Clean Label Oral Strips: What We Leave Out and Why

Clean Label Oral Strips: What We Leave Out and Why

By Jack Zheng, MS Pharmacy -- Founder of MIHIYO Labs

Summary

A clean label oral dissolving strip is not excipient-free. The real goal is to leave out high-sugar carriers, water-heavy syrup systems, and add-ons that do not improve dose delivery or stability. Recent oral-film reviews show that an ODS still needs a purposeful polymer matrix, but liquid-medicine and gummy studies explain why formulators try to avoid other baggage: a 2024 survey found sugar in 14 of 15 pediatric liquid medicines, and a 2025 stability study showed compounded beta-blocker liquids needed preservatives and stayed stable for only 15 days at 25 C/60% relative humidity. For MIHIYO Labs, clean label means fewer passengers and clearer formulation logic.

What does a clean label oral strip actually mean?

Clean label oral strip does not mean no excipients. It means every inactive ingredient has to justify its place in the formula. If a material improves film formation, dose uniformity, taste control, or stability, it belongs. If it is there only because another dosage form needs syrup bulk, bottled-water preservation, or extra cosmetic padding, I would rather leave it out.12

That distinction matters because oral dissolving strips are already a specific kind of delivery system. Reviews of oral thin films and orodispersible films describe them as hydrophilic polymer matrices that disintegrate quickly in the mouth, often without water, and whose performance depends on the polymer, plasticizer, drug load, and packaging being chosen as one system rather than as disconnected ingredients.134 In other words, the strip is not a magic sheet with actives dusted on top. It is a deliberately engineered matrix.

When I use clean-label language in formulation, I am not trying to win a shortest-ingredient contest. I am trying to avoid ingredients that are compensating for a less efficient dosage architecture. A dry strip should not need the same sugar burden as a syrup. It should not need the same preservative logic as a water-based bottle. And it should not carry filler that has no job beyond making a panel look familiar.

Which ingredients do I try to leave out, and why?

The first category is high-sugar carrier systems. That is where a lot of "clean label" talk becomes practical instead of decorative. In a 2024 analysis of 15 commonly prescribed pediatric liquid medicines, only one product was sugar-free.5 A much older but still useful 1988 survey of pediatric liquid medicines found sugar contents from 29.4% to 61.2%, with sucrose the most common sugar.6 Those are medicines, not supplement strips, but the dosage-form lesson is obvious: once you build around a sweet liquid vehicle, sugar often stops being a trace taste tool and starts becoming structural baggage.

The second category is water-heavy systems that force a preservative strategy. Water is not neutral. It changes chemical stability, microbiology, packaging needs, and shelf-life expectations. A 2025 compounding study on pediatric beta-blocker liquids found that two of the three formulations needed citric acid plus potassium sorbate to ensure preservative efficacy, and room-temperature stability at 25 C/60% relative humidity was 15 days.7 That is not a criticism of liquids as a class. It is a reminder that once the dosage form starts as a wet system, the excipient stack often grows because the environment is harder to control.

The third category is soft, consumer-friendly matrices that still need rescue engineering to protect unstable actives. A 2026 vitamin C gummy paper opened with the core problem directly: water-soluble vitamin C is hard to keep stable during gummy processing and storage, so the authors built a more elaborate liposomal matrix to protect it.8 Again, the point is not that gummies are bad. The point is that a dosage form can look simple to a customer while becoming chemically complicated behind the scenes.

For me, those are exactly the ingredients and systems worth questioning first: sugar syrup when a lighter sweetening approach can work, bottled-water architecture when a dry unit strip can work, and decorative filler that adds label length without improving the strip.

Clean-label oral strip design removes structural baggage from the dosage form A dry oral strip keeps purposeful film components while leaving out sugar-heavy syrup systems, water-heavy preservation logic, and filler without a formulation job. What I try to leave out What still earns a place Sugar-heavy carrier Syrup bulk doing the main taste job Film-forming polymer Matrix that casts, dries, and dissolves Water-heavy bottle system More preservation and storage burden Targeted taste support Only enough sweetening to make use practical Label-length filler Inactive ingredients without a clear job Unit pouch protection Moisture barrier is part of the dosage form Clean label means fewer passengers, not zero excipients

What do the studies show about those trade-offs?

The clean-label argument is only credible if it stays anchored to formulation trade-offs rather than aesthetics.

Design question Clean-label strip direction What other formats often need Why I care Source
Sugar carrier Sweetness can be handled inside a low-mass polymer film instead of a syrup base. Many pediatric liquids still rely on sugar-bearing vehicles; one older survey found 29.4% to 61.2% sugar. Sugar should be a taste tool, not the delivery architecture. Rao 2024; Ng and Hassali 198856
Water phase and preservation ODFs are stable polymer films that often do not need water for use. Beta-blocker liquids needed citric acid and potassium sorbate, with 15-day stability at 25 C/60% RH. Water creates extra chemical and microbiological work. Morath 2022; Dubois 202547
Stability burden A dry film can remain stable for months if the API and matrix match. Unstable gummy actives may need extra protective technologies during processing and storage. Fewer stability problems usually means fewer compensating excipients. Kegele 2025; Amalraj 202689
Excipient purpose Film reviews focus on polymer, plasticizer, taste, and packaging as core functions. Long ingredient lists often grow when the dosage form itself creates more problems to solve. I want each inactive to have a narrow, defensible job. Ozakar 2021; Krampe 2016; Pacheco 2021123

The sugar row matters because it exposes how "clean label" can drift into theater. If sweetness is needed for compliance, that is a real formulation job. But there is a large difference between using a light sweetening system inside a thin strip and building the whole dosage form around a sweetened bulk vehicle. The 2024 pediatric-liquid analysis and the older Singapore survey both point the same way: sugar often becomes a major structural feature of oral liquids, not a minor finishing touch.56

The water-and-preservatives row matters because many consumers do not see those ingredients as part of the dosage-form decision. They should. A dry strip starts from a different stability position than a bottle. Morath and colleagues describe ODFs as stable polymer films that disintegrate easily, often without water.4 The pediatric beta-blocker paper shows the practical opposite case: once the product is a liquid suspension, the formulation may need acidification, preservatives, refrigeration logic, or shorter room-temperature windows.7

The stability row is where hype needs to stop. A strip is not automatically stable just because it is dry. The 2025 OrPhyllo study monitored compounded orodispersible films for 180 days and found that some actives stayed within the acceptable 90% to 110% recovery window for the full period, while other formulations held only 60 or 90 days.9 That is real formulation science. The format helps, but the active ingredient still sets the ceiling. The gummy paper reinforces the same lesson from the other side: when a dosage form is harsher on an unstable active, formulators have to build in more protection.8

Clean-label trade-offs for oral strips compared with liquid and gummy systems Studies show sugar is common in pediatric liquids, room-temperature liquid stability can be short, gummies may need extra stability engineering, and dry films can remain stable for months when the active and matrix fit each other. Question Observed number What it says Sugar in liquid meds Pediatric liquid survey 14 of 15 Only one product was sugar-free Sugar is often structural in sweet liquid dosage forms Older syrup analysis Pediatric liquid medicines 29.4% to 61.2% Measured sugar content High sweetness can become the delivery architecture itself Liquid room-temp window Compounded beta-blockers 15 days At 25 C and 60% RH Wet systems often need extra preservative and storage logic Dry film stability Ambient ODF study 60 to 180 days Depends on the active and matrix Dry film can reduce baggage, but stability is still ingredient-specific

Why a strip still needs some excipients

This is the part clean-label marketing often gets wrong. A good strip is not "just the active ingredient." The matrix itself is dosage-form function. Oral thin-film reviews note that polymer commonly makes up a large share of film mass, because the strip has to cast, dry, flex, and disintegrate in a controlled way.1 Natural-polymer reviews make the same point in a different language: pullulan, maltodextrin, starch, alginate, pectin, and related materials are chosen because they influence mechanical strength, mucoadhesion, and fast disintegration.3

So I do not think the right formulation goal is zero excipients. I think the right goal is the smallest justified set of excipients. A polymer has a job. A plasticizer has a job. A taste-management component may have a job if the active is naturally unpleasant. Packaging has a job because moisture can wreck a film even when the ingredient list looks elegant on paper.2 Clean label is not ingredient denial. It is ingredient accountability.

There is also a payload reality. A strip only has so much room. If the format can carry a limited amount of non-active material before mouthfeel, thickness, or disintegration starts to suffer, then every inactive ingredient has to earn its space. That is one reason I prefer to leave out bulk that belongs more naturally to syrups, gummies, or chewables.

What does this mean for MIHIYO products?

For Energy-Focus, Mood-Boost, and Sleep-Support, the clean-label question is less "How short can the panel be?" and more "What are we refusing to solve with the wrong architecture?" I would rather start with a dry unit strip, a film-forming system that disintegrates cleanly, and the lightest taste strategy that still makes the product usable. That is the same formulation mindset behind our recent discussions of oral dissolving film polymers and oral dissolving strip shelf life: the dosage form works only when the matrix and the protection system make sense together.

This is also where I want to keep the evidence boundary clear. The papers cited here are on oral films, pediatric liquids, and gummies in research or compounding settings. They are not head-to-head trials on finished MIHIYO retail products. What they do show, clearly, is why a formulator who values cleaner architecture would try to avoid sugar-heavy carriers, avoid water phases that force preservative strategy, and keep the inactive system narrow and purposeful.1279

The practical implication is not that every strip should advertise itself as "free from everything." That language usually becomes sloppy fast. The practical implication is that when I leave something out, I want a formulation reason: better dose economy, lower moisture burden, fewer compensating additives, or a cleaner path to stability.

Where can clean-label language still mislead people?

The first risk is pretending that clean label means better efficacy. It does not. A shorter ingredient list cannot rescue a weak active, a poor dose, or a bad absorption pathway. Clean label is about dosage-form discipline, not a shortcut to clinical performance.

The second risk is pretending that natural always means better. Natural polymers are important and useful in oral films, and the literature on pullulan, starch, pectin, and related materials is strong.3 But "natural" is still not the decision rule. The real decision rule is whether the polymer gives the strip the right strength, disintegration, and stability profile.

The third risk is pretending that every active belongs in a small dry film. It does not. The OrPhyllo stability paper is helpful precisely because it shows different outcomes for different ingredients in the same basic platform.9 Some molecules behave well. Some do not. Sometimes the honest answer is that a strip is the wrong place to force a product idea.

The bottom line

A clean label oral strip is not about making the ingredient list look empty. It is about leaving out sugar-heavy carriers, water-heavy preservative systems, and filler that does not improve the strip's real job.567 The oral-film literature supports that philosophy, but it also makes the limit clear: a strip still needs a purposeful polymer matrix, appropriate packaging, and excipients that earn their place.1234 For MIHIYO Labs, that is the formulation standard that matters most. Less baggage, more function, and no ingredient riding along without a reason.

References

  1. Sevinc Ozakar R, Ozakar E. Current Overview of Oral Thin Films. Turk J Pharm Sci. 2021;18(1):111-121. PMID: 33634686 / DOI: 10.4274/tjps.galenos.2020.76390. <https://pubmed.ncbi.nlm.nih.gov/33634686/>
  2. Krampe R, Visser JC, Frijlink HW, Breitkreutz J, Woerdenbag HJ, Preis M. Oromucosal film preparations: points to consider for patient centricity and manufacturing processes. Expert Opin Drug Deliv. 2016;13(3):405-413. PMID: 26559519 / DOI: 10.1517/17425247.2016.1118048. <https://pubmed.ncbi.nlm.nih.gov/26559519/>
  3. Pacheco MS, Barbieri D, da Silva CF, de Moraes MA. A review on orally disintegrating films (ODFs) made from natural polymers such as pullulan, maltodextrin, starch, and others. Int J Biol Macromol. 2021;178:504-513. PMID: 33647337 / DOI: 10.1016/j.ijbiomac.2021.02.180. <https://pubmed.ncbi.nlm.nih.gov/33647337/>
  4. Morath B, Sauer S, Zaradzki M, Wagner AH. Orodispersible films - Recent developments and new applications in drug delivery and therapy. Biochem Pharmacol. 2022;198:115036. PMID: 35427572 / DOI: 10.1016/j.bcp.2022.115036. <https://pubmed.ncbi.nlm.nih.gov/35427572/>
  5. Rao A, Bhad B, Upadhyay V, Bhatia R, Parikh M. An Analysis of pH and Sugar Content of Commonly Prescribed Pediatric Liquid Medications: The Current Indian Scenario. J Pediatr Pharmacol Ther. 2024;29(4):354-361. PMID: 39144383 / DOI: 10.5863/1551-6776-29.4.354. <https://pubmed.ncbi.nlm.nih.gov/39144383/>
  6. Ng MT, Hassali MA. An analysis of sugar content of commonly used pediatric liquid medicines--its relevance to dentistry. Singapore Dent J. 1988;13(1):9-12. PMID: 3154999. <https://pubmed.ncbi.nlm.nih.gov/3154999/>
  7. Dubois L, Bouguergour C, Paoli-Lombardo R, Castera-Ducros C, Jean C, Fuchs M, et al. Compounding and stability studies of liquid oral formulations of beta-blockers (bisoprolol, betaxolol, and nadolol) for paediatric patients. J Pharm Pharm Sci. 2025;28:15387. PMID: 41409535 / DOI: 10.3389/jpps.2025.15387. <https://pubmed.ncbi.nlm.nih.gov/41409535/>
  8. Amalraj A, Abraham EK, Nair AS, Sivarajakumar P, Gopi S. Development of Highly Stable Vitamin C Gummies Using Innovative In Situ Soft Sphere Integrated (ISSI) Liposomal Technology: Characterization and In Vitro Release Studies. ACS Omega. 2026;11(3):12627-12640. PMID: 41658177 / DOI: 10.1021/acsomega.5c09739. <https://pubmed.ncbi.nlm.nih.gov/41658177/>
  9. Kegele CS, Marianni B, Polonini H. Personalized Orodispersible Films Compounded with OrPhyllo Ready-to-use Base: API Compatibility and Evidence-Based Beyond-Use Dates. Int J Pharm Compd. 2025;29(6):174-183. PMID: 41401040. <https://pubmed.ncbi.nlm.nih.gov/41401040/>

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.